| 1 |
23116626 | Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. | 2013 Apr |
1 |
| 2 |
24074788 | Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient. | 2013 Aug |
1 |
| 3 |
21892704 | The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. | 2012 Jan |
2 |
| 4 |
23045588 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. | 2012 Nov 10 |
1 |
| 5 |
21321298 | Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. | 2011 Mar 20 |
1 |
| 6 |
22018631 | Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8ยท1 years median follow-up. | 2011 Nov |
1 |
| 7 |
21188118 | FACE: the barefaced facts of AI potency. | 2010 Oct 27 |
2 |
| 8 |
19528136 | Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. | 2009 Jun |
1 |
| 9 |
19914548 | Update of the BIG 1-98 Trial: where do we stand? | 2009 Oct |
2 |
| 10 |
18083065 | Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. | 2008 Jan |
1 |
| 11 |
19096768 | Understanding the BIG results: Insights from the BIG 1-98 trial analyses. | 2008 Dec |
2 |
| 12 |
17200148 | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. | 2007 Feb 10 |
1 |
| 13 |
17492927 | The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. | 2007 May |
2 |
| 14 |
17912636 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. | 2007 |
3 |
| 15 |
16500237 | The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98. | 2006 Feb |
1 |
| 16 |
16730270 | The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. | 2006 Apr |
1 |
| 17 |
16944964 | Cardiovascular safety profiles of aromatase inhibitors : a comparative review. | 2006 |
2 |
| 18 |
17257462 | Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. | 2006 Dec |
2 |
| 19 |
16100522 | The effects of aromatase inhibitors on lipids and thrombosis. | 2005 Aug |
1 |
| 20 |
16382061 | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. | 2005 Dec 29 |
3 |